00:00 I would say that it is a substantial change because this category of patients so-called unfit for chemotherapy
00:07 received either palliative therapy, or oral hypomethylants that gave results but were not satisfactory.
00:20 This therapy allowed us to treat more patients than before in an adequate way,
00:26 but also to obtain results that are not substantially different from those of intensive chemotherapy.
00:33 We are particularly satisfied because in practice we are replicating the results of the experimental trials
00:41 that led to the registration.
00:44 I must say that already in 2020 this therapy has been made available in Italy by the IFA
00:51 thanks to our request, to the request of the clinical scientific community,
00:56 so a very large number of patients throughout the nation with acute myeloid leukemia,
01:02 I repeat, not able to receive an intensive therapy,
01:07 have had this treatment with largely satisfactory results,
01:11 so we hope to continue in the future.
